Iqirvo could stabilize major biliary cholangitis development after long-term use
November 20, 2025
3 min watch
On this video, Nancy S. Reau, MD, FAASLD, AGAF, discusses long-term information from the ELATIVE open-label extension trial of Iqirvo in sufferers with major biliary cholangitis.
Outcomes offered at The Liver Assembly demonstrated 72% of sufferers achieved a biochemical response after 182 weeks of receiving Iqirvo (elafibranor, Ipsen). Additional, alkaline phosphatase normalized in 19% of sufferers which “was a extremely thrilling metric,” Reau, the Richard B. Capps Chair of Hepatology, affiliate director of strong organ transplantation and part chief of hepatology at Rush College, stated.
Liver harm markers both improved or stabilized, together with alanine aminotransferase which, “dropped markedly within the first 26 weeks and remained secure all through the 182-week length,” Reau stated. She added gamma-glutamyl transferase additionally had an identical pattern.
Enhancements in liver fibrosis and fibrogenesis had been reported in sufferers receiving elafibranor, with important enhancements noticed in Professional-C3 and Enhanced Liver Fibrosis scores. Elafibranor use considerably improved fatigue and pruritus.
“Elafibranor led to speedy and sustained responses in clinically related biomarkers however stabilized or improved markers of fibrosis and fibrogenesis,” Reau instructed Healio. “This means that over the three.5 years of this research, illness development was stabilized, if not prevented. This, once more, is a exceptional achievement for sufferers with major biliary cholangitis that haven’t obtained or had been illiberal to ursodeoxycholic acid.”
For extra info:
Nancy S. Reau, MD, FAASLD, AGAF, can be reached at nancy_reau@rush.edu.
Sources/Disclosures
Supply:
Healio Interviews
Reference:
- Levy C, et al. Lengthy-term therapy with elafibranor results in biochemical and symptomatic enhancements for a minimum of 3 years in sufferers with major biliary cholangitis. Offered at: The Liver Assembly; Nov. 7-11, 2025; Washington (hybrid assembly).
Disclosures:
This research was funded by Ipsen. Reau studies consulting for Gilead Sciences and Ipsen. Please see the research for all different authors’ related monetary disclosures.
Ask a scientific query and faucet into Healio AI’s data base.
- PubMed, enrolling/recruiting trials, tips
- Medical Steering, Healio CME, FDA information
- Healio’s unique every day information protection of scientific information
